Abstract
Jingming Wang1,2, Maximilian Linxweiler2,4, Wei Yang1,2, Timothy A. Chan1,2,3 and Luc G.T. Morris1,4
1 Immunogenomics Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Correspondence to:
Timothy A. Chan, | email: | chant@mskcc.org |
Luc G.T. Morris, | email: | morrisl@mskcc.org |
Keywords: immune; microenvironment
Received: April 22, 2019 Accepted: May 13, 2019 Published: June 11, 2019
ABSTRACT
The mutagenic effects of tobacco smoking increase the risk of the development of cancers of the lung, head and neck, and other anatomic sites. In a comparison of squamous cell carcinomas of the lung and the head and neck, we find that the immunomodulatory effects of smoking differ based on anatomic site. In both sites, the mutational signature of smoking is strongly associated with somatic mutational load. In head and neck squamous cell carcinoma, the mutational signature of tobacco exposure is associated with a strongly immunosuppressive tumor microenvironment. In contrast, in lung squamous cell carcinoma, the opposite effect is seen, with the tumor immune microenvironment significantly more inflamed. These effects are mirrored in rates of response to immune checkpoint inhibitor immunotherapy, which tend to be higher in smokers with lung cancer, but lower in smokers with head and neck cancer. We find a similarly strong immunosuppressive effect of smoking in non-cancerous lung epithelium. Taken together, our findings show that the effects of mutational signatures on the immune microenvironment and response to immunotherapy can be affected by context such as cancer type, anatomic site, and histology.